Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027

LONDON, August 3, 2017 /PRNewswire/ --

North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing 

The global pharmaceutical contract manufacturing market [https://www.visiongain.com/Report/1942/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Forecast-2017-2027 ] was valued at $76.6bn in 2016 and is expected to grow at a CAGR of 6.6% in the first half of the forecast period. Between 2011 and 2016, the top 5 emerging market CMOs grew at a CAGR of 13.6%, whereas the leading developed market CMOs grew at a CAGR of 1.7% over the same period.

(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you: Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 311-page report you will receive 184 tables and 111 figures - all unavailable elsewhere.

The 311-page report provides clear detailed insight into the pharmaceutical CMOs market [https://www.visiongain.com/Report/1942/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Forecast-2017-2027 ] . Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope: 

- Global Pharmaceutical Contract Manufacturing Market forecast from 2017-2027 [https://www.visiongain.com/Report/1942/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Forecast-2017-2027 ] : - API Manufacturing - FDF Manufacturing - Other Services

- This report profiles 30 leading CMOs in North America, Europe, Japan, China and India: - Catalent - Patheon - Baxter - AbbVie - Pfizer - Lonza - Evonik Degussa - Royal DSM - Boehringer Ingelheim - Fareva - Aenova - Famar - Vetter - Almac - Delpharm - Siegfried - Corden - Recipharm - Aesica - Nipro - Daito - Teva API - Esteve Quimica - Euticals - Zhejiang Hisun Pharmaceuticals - Zhejiang Huahai Pharmaceuticals - Shandong Xinhua Pharmaceuticals - Aurobindo Pharma - Divis Laboratories - Dr. Reddy's Laboratories

- The content of each profile differs, depending on the organisation. In general, a profile gives the following information:

- Overview of the company's contract manufacturing services and operations

- Analysis of recent financial performance - annual revenue for CMO services, including some data on operating profit and margins

- Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations

- SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2016 onwards

- Forecasting of pharmaceutical manufacturing revenue to 2027, as well as projected operating profit and margin for some companies.

Visiongain's [https://www.visiongain.com ] study is intended for anyone requiring commercial analyses for the top 30 pharmaceutical CMOs market [https://www.visiongain.com/Report/1942/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Forecast-2017-2027 ] . You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027: [https://www.visiongain.com/Report/1942/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Forecast-2017-2027 ] North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1942/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Forecast-2017-2027

Companies Mentioned in the Report: 

Abbott Laboratories

Abic

AbbVie

Actavis

Adamas Pharmaceuticals

Aegerion

Aenova Group

Aesica Pharmaceuticals

Agennix

Aguettant

AlgoNomics

Alliance Medical Products

Almac Group

Alpharma

Amgen

AMYRA Biotech

Andeno

Apexigen

Aptuit

Archimica

Arecor

ArGEN-X

Astellas

AstraZeneca

Athera Biotechnologies

Aurobindo Pharma

Avalanche Biotechnologies

Banner Life Sciences

BaroFold

Barr-Pliva

BASF

Baxter BioPharma Solutions

Bayer

BC Partners

Becton and Dickinson (BD)

Beijing Double-Crane Pharmaceutical

Bentley

Biocraft

Biogal

Bionomics

Biotest

BioWa

Boehringer Ingelheim

Bridgepoint Capital

Bristol-Myers Squibb (BMS)

Britest

Canyon

Carbogen Amcis

Cardinal Health

Catalent

Celladon

Celldex Therapeutics

Celsion

CEVEC Pharmaceuticals

Chemtrix BV

China National Pharmaceutical Group (SInopharm)

Chirotech

Circadian Technologies

Cleveland BioLabs

Cobra Biomanufacturing

Companies House

CordenPharma

Corvette Pharmaceutical Services

Daiichi Sankyo

Daito

DecImmune Therapeutics

Delmas Perfusion

Delpharm

Divis Laboratories

DPx Holdings

Dr. Reddy's Laboratories

Dragenopharm Apotheker Pueschl and Swiss Caps

Eclipse Therapeutics

Eisai

Eli Lilly

EmulTech

Esteve Quimica

Euro Vital Pharma

Euticals

Evonik Degussa

Excella

Exelixis

Famar

Fareva

Farmaprojects

Frazier Healthcare

Fuyang Xinghai Investment

Genentech

Genzyme

GSK

Corixa

Haupt Pharma

Health Canada

Hejiang Jiang Yuan Tang Biotechnology

Human Genome Sciences

ICI

Immune Pharmaceuticals

Immunomedics

Index Ventures

Indoco Remedies

Intellect Neurosciences

International Chemical Investors Group

Ivax API

JK Pharmaceutical

JLL Partners

Johnson & Johnson (J&J)

Kadmon

Laboratoires Besins

Lanxess Corporation

LBO Italia Investimenti s.r.l

Lonza

Marinopoulos Group.

MedImmune

Merck KGaA

Merck Serono

Mesoblast

Molecular Partners

Moody's Corporation

Mylan

Nipro Corporation

Novartis

Novasep

Novozymes

NPS

OctoPlus

OncoMed Pharmaceuticals

Opthea

Osiris Therapeutics

Otsuka Pharmaceutical

Pantec

Patheon

Perrigo

PFC

Pfizer

Pharmacia

Pharmacyclis

Pharmintraco

Piramal

Plantex

Poli Industria Chimica

Progenics Pharmaceuticals

Prosintex

R5 Pharmaceuticals

RAG AG

Ranbaxy Labs

Recipharm

Regeneus

Relthy Laboratorios

Relypsa

Respirics

Rexim

Roche

Royal DSM

Sandoz

Sanofi

Sanwa Kagaku Kenkyusho

Schering

ScinoPharm

Seattle Genetics

Sentry BioPharma Services

Servier

Shandong Tianda Biological Pharmaceutica

Shandong Xinhua Pharmaceutical

Shanghai Pharmaceutical

ShangPharma

Shire

Sicor

Siegfried

Sigmar Italia

Silverfleet Capital

Sinochem

SkyePharma

Solvay

Sun Pharma

Supernus Pharmaceuticals

SurModics

Swedbank

Swedish Orphan Biovitrium AB (Sobi)

Synkem

Syntex

Synthon

Takeda

Temmler Group

Tessenderlo Group

Teva Pharmaceutical Industries

Theramax

Tianjin Tianyo Pharmaceuticals

Tianma Tianji

Tunitas Therapeutics

UCB

UMN Pharma

UniQure

Vetter Pharma

Vidara

ViroPharma

Vivante GMP Solutions

VTU Technology

West Pharma

Wockhardt

XOMA

Yiwu Huayi Investment

Zhangjiang Biotech & Pharmaceutical Base Company

Zhejiang Hisun Pharmaceutical

Zhejiang Huahai Pharmaceuticals

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


    Photo: 
    http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg


SOURCE Visiongain Ltd